|
CURRENT ISSUE VOLUME 19 NO. 4 JULY/AUGUST 2008
 Money Talks
Prescription for Success
By Beste Alpargun
Some scientists in Halifax are excited - for good reason. They are moving nearer to the commercialization of a novel vaccine technology that helps ensure a long period of immunity with a single dose without boosting or significant side effects. The VacciMax® platform, which can improve existing vaccines or help in the development of new vaccines for humans and animals, has the potential for both preventative and therapeutic use. This includes vaccines in the pipeline for infectious diseases and cancer.
Let us put this into perspective. According to a report from Kalorama Information, the global vaccine market is expected to top US$10 billion in 2007 and US$23.8 billion in 2012. The most dramatic growth is predicted to occur with vaccines for influenza (estimated US$4 billion) and hepatitis (estimated US$1.5 billion in 2012). Another high-growth segment will be cancer vaccines, which currently sit at US$135 million but are forecast to hit US$8 billion in 2012.
This is a huge market for a small, early-stage company like ImmunoVaccine Technologies Inc. and its technology, VacciMax®. So what is the company's strategy?
Get the full story with a free one-year subscription to Atlantic Business Magazine.
Click HERE to Subscribe.
|
